GOCM
PVLA

Green Owl Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Green Owl Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,625
Closed -$1.24M – 128
2015
Q2 		$1.24M Buy
+5,625
New +$1.24M 0.88% 31

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Green Owl Capital Management's PVLA Position: Q3 2015 in Review

Green Owl Capital Management sold out of Palvella Therapeutics (PVLA) in Q3 2015, closing a stake of 5,625 shares — an estimated $1.24M sold.

Green Owl Capital Management first reported a position in PVLA in Q2 2015 and held it in 1 quarter. The position peaked at $1.24M in Q2 2015. 13 funds tracked by Wall St. Rank hold PVLA as of Q3 2015.

  • Green Owl Capital Management reported no remaining Palvella Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Green Owl Capital Management sold 5,625 Palvella Therapeutics shares in Q3 2015, an estimated $1.24M.
  • Green Owl Capital Management first reported a position in Palvella Therapeutics in Q2 2015 and held it in 1 quarter.
  • Green Owl Capital Management's Palvella Therapeutics position peaked at $1.24M in Q2 2015.
  • 13 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2015.

Based on Green Owl Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.